Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016
Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which h...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890062/ https://www.ncbi.nlm.nih.gov/pubmed/29636987 http://dx.doi.org/10.1136/esmoopen-2017-000315 |
_version_ | 1783312793290670080 |
---|---|
author | López, Roberto Ivan Castro, Jenny Lissette Cedeño, Heidy Cisneros, Dagoberto Corrales, Luis González-Herrera, Ileana Lima-Pérez, Mayté Prestol, Rogelio Salinas, Roberto Soriano-García, Jorge Luis T Zavala, Alejandra Zetina, Luis Miguel Zúñiga-Orlich, Carlos Eduardo |
author_facet | López, Roberto Ivan Castro, Jenny Lissette Cedeño, Heidy Cisneros, Dagoberto Corrales, Luis González-Herrera, Ileana Lima-Pérez, Mayté Prestol, Rogelio Salinas, Roberto Soriano-García, Jorge Luis T Zavala, Alejandra Zetina, Luis Miguel Zúñiga-Orlich, Carlos Eduardo |
author_sort | López, Roberto Ivan |
collection | PubMed |
description | Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which has substantially improved through strategic changes in treatment and in the management of patients. As opposed to other metastatic cancers where first-line regimens are often determined, mCRC requires special attention because there is controversy in the possible combinations of the available drugs and the different periods of duration for each patient. Each combination must seek to be effective and to generate the minimum adverse effects as possible. Instead of giving the first-line regimen until the tumour progresses, treatment is often individualised. Furthermore, up to 60% of colorectal tumours are considered non-mutated or wild-type CRC. Not harbouring mutations in the RAS family of genes or mutations in the signalling pathways of the epidermal growth factor receptor causes a null response to anti-epidermal growth factor receptor antibody therapy, which implies even more complex considerations regarding its management. The primary objective of this consensus is to address the main scenarios of mCRC in order to warrant the most appropriate therapeutic intervention for these patients in the Central American and the Caribbean (CAC) region. This can lead to better clinical outcomes as well as quality of life for palliative patients. This document includes the formal expert consensus recommendations for scenarios of mutated and non-mutated mCRC, including synchronous or metachronous disease, management of mCRC with liver and lung metastasis, resectable, potentially resectable or non-resectable tumours and local in the CAC context. |
format | Online Article Text |
id | pubmed-5890062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58900622018-04-10 Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 López, Roberto Ivan Castro, Jenny Lissette Cedeño, Heidy Cisneros, Dagoberto Corrales, Luis González-Herrera, Ileana Lima-Pérez, Mayté Prestol, Rogelio Salinas, Roberto Soriano-García, Jorge Luis T Zavala, Alejandra Zetina, Luis Miguel Zúñiga-Orlich, Carlos Eduardo ESMO Open Review Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which has substantially improved through strategic changes in treatment and in the management of patients. As opposed to other metastatic cancers where first-line regimens are often determined, mCRC requires special attention because there is controversy in the possible combinations of the available drugs and the different periods of duration for each patient. Each combination must seek to be effective and to generate the minimum adverse effects as possible. Instead of giving the first-line regimen until the tumour progresses, treatment is often individualised. Furthermore, up to 60% of colorectal tumours are considered non-mutated or wild-type CRC. Not harbouring mutations in the RAS family of genes or mutations in the signalling pathways of the epidermal growth factor receptor causes a null response to anti-epidermal growth factor receptor antibody therapy, which implies even more complex considerations regarding its management. The primary objective of this consensus is to address the main scenarios of mCRC in order to warrant the most appropriate therapeutic intervention for these patients in the Central American and the Caribbean (CAC) region. This can lead to better clinical outcomes as well as quality of life for palliative patients. This document includes the formal expert consensus recommendations for scenarios of mutated and non-mutated mCRC, including synchronous or metachronous disease, management of mCRC with liver and lung metastasis, resectable, potentially resectable or non-resectable tumours and local in the CAC context. BMJ Publishing Group 2018-03-15 /pmc/articles/PMC5890062/ /pubmed/29636987 http://dx.doi.org/10.1136/esmoopen-2017-000315 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Review López, Roberto Ivan Castro, Jenny Lissette Cedeño, Heidy Cisneros, Dagoberto Corrales, Luis González-Herrera, Ileana Lima-Pérez, Mayté Prestol, Rogelio Salinas, Roberto Soriano-García, Jorge Luis T Zavala, Alejandra Zetina, Luis Miguel Zúñiga-Orlich, Carlos Eduardo Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 |
title | Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 |
title_full | Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 |
title_fullStr | Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 |
title_full_unstemmed | Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 |
title_short | Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 |
title_sort | consensus on management of metastatic colorectal cancer in central america and the caribbean: san josé, costa rica, august 2016 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890062/ https://www.ncbi.nlm.nih.gov/pubmed/29636987 http://dx.doi.org/10.1136/esmoopen-2017-000315 |
work_keys_str_mv | AT lopezrobertoivan consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT castrojennylissette consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT cedenoheidy consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT cisnerosdagoberto consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT corralesluis consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT gonzalezherreraileana consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT limaperezmayte consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT prestolrogelio consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT salinasroberto consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT sorianogarciajorgeluis consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT tzavalaalejandra consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT zetinaluismiguel consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 AT zunigaorlichcarloseduardo consensusonmanagementofmetastaticcolorectalcancerincentralamericaandthecaribbeansanjosecostaricaaugust2016 |